Talazoparib for advanced breast cancer with DNA repair defects
Treatments studied
Part of Cancer clinical trials.
This trial studies talazoparib (a targeted pill) in people with advanced breast cancer whose tumors have problems repairing certain DNA damage. If your tumor has these specific “DNA repair” defects, the medicine may work better and stop the cancer from growing.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are age 19 or older, and your breast cancer is metastatic or cannot be removed with surgery
- Your tumor test shows a DNA repair defect called homologous recombination deficiency (HRD), such as a BRCA1/2 or other listed gene mutation or a positive RAD51 lab test
- You have already had a taxane chemotherapy, unless you couldn’t take it
- Your cancer has shown progression on imaging during/after the most recent treatment (or within 6 months after adjuvant treatment), and at least 3 weeks have passed since your last chemo
- You haven’t taken a PARP inhibitor before (with limited exceptions), and you must have recent blood/organ test results within required ranges
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a drug called talazoparib (a PARP inhibitor) for advanced breast cancer that has a specific DNA repair defect (HRD) or a BRCA mutation. The goal is to see if the drug works better when the patient's tumor is tested for this defect just before treatment.
This trial tests a new combination of targeted therapies (saruparib plus camizestrant or hormone therapy) against standard treatments for people with a specific type of advanced breast cancer. It may be a good option if you have a BRCA1, BRCA2, or PALB2 gene mutation and have not yet had treatment for your advanced disease.
This Phase 2 study tests olaparib (a targeted anti-cancer pill) alone or with durvalumab (an immunotherapy) for biliary tract cancers that have specific DNA repair gene changes. It’s for people whose cancer has continued after standard platinum chemotherapy, aiming to slow or control the disease.
This Phase 2 trial tests talazoparib, a targeted cancer medicine, in people with metastatic breast cancer that has a harmful BRCA1 or BRCA2 mutation found in tumor DNA circulating in the blood. If you qualify, the goal is to see how well this treatment works when the mutation is detected this specific way.
This trial studies a new drug called saruparib for people with certain solid tumors that have a specific DNA repair problem (called HRD). It may help if your cancer has progressed after other treatments.
This trial tests a new drug called AZD4956, alone or with other cancer medicines, for people with advanced solid tumors that have certain DNA repair problems (called homologous recombination deficiency). It may be an option if you have breast, ovarian, prostate, or pancreatic cancer with a specific gene change, and you have or haven't had previous PARP inhibitor treatment.
Hear when a new Advanced Breast Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.